Double-Blind, Randomized, Placebo-Controlled Trial of Metoclopramide for Hypersalivation Associated With Clozapine.

Abstract:

:Hypersalivation is a frequent, disturbing, and uncomfortable adverse effect of clozapine therapy that frequently leads to noncompliance. The aim of this study was to examine the efficacy of metoclopramide (dopamine D2 antagonist, antiemetic medication) as an option for management of hypersalivation associated with clozapine (HAC). A 3-week, double-blind, placebo-controlled trial was conducted in university-based research clinics from January 2012 to May 2014, on 58 inpatients treated with clozapine who were experiencing hypersalivation. The subjects were randomly divided into placebo and metoclopramide groups. The starting dose was 10 mg/d. Participants who did not respond were up-titrated 10 mg/d weekly to a total of 30 mg/d during the third week. The number of placebo capsules was increased accordingly up to 3 capsules per day. Primary outcome was the change from baseline to the end of study in the severity of hypersalivation as measured with the Nocturnal Hypersalivation Rating Scale and the Drooling Severity Scale. Secondary outcomes included Clinical Global Impression of Improvement scale and adverse effect scales. Significant improvement on the Nocturnal Hypersalivation Rating Scale was demonstrated in the metoclopramide group from the end of the second week (P < 0.004), and on the Drooling Severity Scale (P < 0.02) in the third week. Clinical Global Impression-Improvement scale scores revealed major improvement. Twenty subjects (66.7%) treated with metoclopramide reported significant decline or total disappearance of HAC in comparison to 8 patients (28.6%) who received placebo (P = 0.031). No adverse effects to metoclopramide were reported. Metoclopramide was found to be safe and effective for the treatment of HAC.

journal_name

J Clin Psychopharmacol

authors

Kreinin A,Miodownik C,Mirkin V,Gaiduk Y,Yankovsky Y,Bersudsky Y,Lerner PP,Bergman J,Lerner V

doi

10.1097/JCP.0000000000000493

subject

Has Abstract

pub_date

2016-06-01 00:00:00

pages

200-5

issue

3

eissn

0271-0749

issn

1533-712X

journal_volume

36

pub_type

杂志文章,多中心研究,随机对照试验
  • Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial.

    abstract::A double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 weeks of treatment with risperidone in the management of 48 adolescent and adult patients with Tourette syndrome. Twenty-four patients were randomly assigned to treatment with risperidone in doses of 0.5 to 6.0 mg/da...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200202000-00006

    authors: Dion Y,Annable L,Sandor P,Chouinard G

    更新日期:2002-02-01 00:00:00

  • International Study of Expert Judgement on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: V. Treatment strategies in panic disorder, 1992-1997.

    abstract::The objective of this study was to assemble expert clinical experience and judgment regarding the treatment of panic disorder in a systematic, quantitative manner, particularly with respect to changes during the past 5 years. A panel of 73 internationally recognized experts in the field of pharmacotherapy of anxiety a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199812001-00006

    authors: Uhlenhuth EH,Balter MB,Ban TA,Yang K

    更新日期:1998-12-01 00:00:00

  • Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

    abstract:PURPOSE:This post hoc meta-analysis evaluated the efficacy and safety of desvenlafaxine 50 and 100 mg versus placebo across age groups and severity of depression at baseline in patients with major depressive disorder. METHODS:Data from placebo and desvenlafaxine 50-mg and 100-mg dose arms were pooled from 9 short-term...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0000000000000674

    authors: Mosca D,Zhang M,Prieto R,Boucher M

    更新日期:2017-04-01 00:00:00

  • A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis.

    abstract::This study evaluates how much agreement there is between subjective reports of adherence to antipsychotic medication and objective or derived measures of adherence in first-episode psychosis (FEP) and asks if any adherence measure could approximate a gold standard based on correlation to symptom improvement in the ear...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181ca03df

    authors: Cassidy CM,Rabinovitch M,Schmitz N,Joober R,Malla A

    更新日期:2010-02-01 00:00:00

  • Increased lithium serum and red blood cell concentrations during ketorolac coadministration.

    abstract::Case reports of a lithium-ketorolac drug interaction have been published, but no formal investigation of this interaction has been conducted. The objective of the study presented here was to determine significant changes in lithium serum and red blood cell (RBC) concentrations after lithium and ketorolac (oral formula...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199802000-00006

    authors: Cold JA,ZumBrunnen TL,Simpson MA,Augustin BG,Awad E,Jann MW

    更新日期:1998-02-01 00:00:00

  • Concomitant use of acetylcholine esterase inhibitors and urinary antispasmodics among Finnish community-dwelling persons with Alzheimer disease.

    abstract::Concomitant use of acetylcholine esterase inhibitors (AChEIs) and anticholinergic drugs, such as urinary antispasmodics (UA), is generally considered as inappropriate because of their opposite pharmacological actions. However, prevalence and the duration or factors associated with concomitant use have not been previou...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000218

    authors: Torvinen-Kiiskinen S,Taipale H,Tanskanen A,Tiihonen J,Hartikainen S

    更新日期:2014-12-01 00:00:00

  • Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.

    abstract:BACKGROUND:Some studies have shown that low dose of neuroleptic addition to ongoing antiobsessive treatment might be effective in treatment resistant obsessive-compulsive disorder (OCD). The primary purpose of this study was to evaluate the efficacy of low-dose quetiapine in clomipramine and serotonin reuptake inhibito...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000088900.24613.f2

    authors: Sevincok L,Topuz A

    更新日期:2003-10-01 00:00:00

  • Risk of Mortality Among Patients Treated With Antipsychotic Medications: A Nationwide Population-Based Study in Taiwan.

    abstract::In this nationwide population-based study, we examined whether haloperidol exposure is associated with a higher risk of mortality than are other antipsychotic medications. Patients who newly received monotherapy with chlorpromazine (n = 2133), haloperidol (n = 4454), quetiapine (n = 1513), and risperidone (n = 1046) b...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000451

    authors: Wang LJ,Lee SY,Yuan SS,Yang KC,Yang CJ,Lee TL,Shyu YC

    更新日期:2016-02-01 00:00:00

  • Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

    abstract::This 6-week, double-blind, placebo-controlled study evaluated paliperidone extended-release (ER) as both monotherapy and adjunctive therapy to mood stabilizers and/or antidepressants (MS/ADs) for schizoaffective disorder. Included subjects had a schizoaffective disorder diagnosis; a Positive and Negative Syndrome Scal...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e3181eeb600

    authors: Canuso CM,Schooler N,Carothers J,Turkoz I,Kosik-Gonzalez C,Bossie CA,Walling D,Lindenmayer JP

    更新日期:2010-10-01 00:00:00

  • Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.

    abstract::Weight gain is a problem commonly encountered with antipsychotic treatment and has become more apparent with increasing use of the newer atypical antipsychotics. The adipocyte-derived hormone, leptin, has been associated with body weight and energy homeostasis, and abnormal regulation of leptin could play a role in we...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/jcp.0b013e3180582412

    authors: Zhang XY,Tan YL,Zhou DF,Haile CN,Cao LY,Xu Q,Shen Y,Kosten TA,Kosten TR

    更新日期:2007-06-01 00:00:00

  • Amoxapine versus amitriptyline for continuation therapy of depression.

    abstract::The efficacy of continuation therapy with tricyclic antidepressants has been established in a number of controlled trials. This study investigated the efficacy of continuation therapy with a relatively new antidepressant, amoxapine, using a double-blind controlled comparison with amitriptyline. Subjects met DSM-III cr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Mason BJ,Kocsis JH,Frances AJ,Mann JJ

    更新日期:1990-10-01 00:00:00

  • Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.

    abstract::Idazoxan, a selective alpha 2-adrenergic antagonist, was added to stable doses of fluphenazine treatment in six patients with schizophrenia who participated in a double-blind, placebo-controlled pharmacologic study. Compared with fluphenazine alone, combining idazoxan (mean dose, 120 mg/day) with fluphenazine (mean do...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Litman RE,Hong WW,Weissman EM,Su TP,Potter WZ,Pickar D

    更新日期:1993-08-01 00:00:00

  • The Utility of Low-Dose Aripiprazole for the Treatment of Bipolar II and Bipolar NOS Depression.

    abstract:BACKGROUND:Despite initial reports of efficacy in bipolar depression, multicenter trials did not show aripiprazole to be better than placebo, possibly because the doses used were too high, leading to lower efficacy and high dropout rates. This study evaluated the effects of low-dose aripiprazole. Extensive clinical exp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000636

    authors: Kelly T,Lieberman DZ

    更新日期:2017-02-01 00:00:00

  • Persistence of fluphenazine in plasma after decanoate withdrawal.

    abstract::We discontinued fluphenazine decanoate using a double-blind, crossover random order design, in 12 recent onset clinically stable schizophrenics who had been given fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks for at least 1 year prior to drug withdrawal. Each condition (drug or placebo) lasted 12 weeks....

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Gitlin MJ,Midha KK,Fogelson D,Nuechterlein K

    更新日期:1988-02-01 00:00:00

  • Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level.

    abstract::Medication nonadherence in severe mental disorders is an important clinical issue, but estimates vary between studies. There is a need for valid self-reports for both research and clinical practice. This study examined the level of adherence to prescribed medication in outpatients with severe mental disorders and eval...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3181d2191e

    authors: Jónsdóttir H,Opjordsmoen S,Birkenaes AB,Engh JA,Ringen PA,Vaskinn A,Aamo TO,Friis S,Andreassen OA

    更新日期:2010-04-01 00:00:00

  • Bupropion improves sexual functioning in depressed minority women: an open-label switch study.

    abstract::Minority women often have a unique set of beliefs and expectations about medical treatment. At this time, there is a dearth of research looking at how depressed minority women respond to pharmacological interventions for the sexual concomitants of depression. This was the first study to examine the impact of a medicat...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000194623.07611.90

    authors: Dobkin RD,Menza M,Marin H,Allen LA,Rousso R,Leiblum SR

    更新日期:2006-02-01 00:00:00

  • Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.

    abstract:BACKGROUND:Late-life depression, often in association with anxiety, affects approximately 15% of individuals older than 65 years. Selective serotonin reuptake inhibitors are the first-line treatment but could be responsible of an early exacerbation of anxiety, possibly reduced by a very gradual titration of drugs. The ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e3182905967

    authors: Gibiino S,Mori E,De Ronchi D,Serretti A

    更新日期:2013-08-01 00:00:00

  • Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder.

    abstract::Tolcapone is a catechol-O-methyltransferase (COMT) inhibitor that has shown efficacy in the treatment of Parkinson's disease. The authors undertook the first study on the efficacy of this COMT inhibitor in the treatment of major depressive disorder (MDD). The authors also wanted to assess the effects of tolcapone on t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199908000-00008

    authors: Fava M,Rosenbaum JF,Kolsky AR,Alpert JE,Nierenberg AA,Spillmann M,Moore C,Renshaw P,Bottiglieri T,Moroz G,Magni G

    更新日期:1999-08-01 00:00:00

  • Prediction of individual dosage of nortriptyline in depressed elderly outpatients.

    abstract::Individual daily dosages of nortriptyline (NT) can be predicted from administration of a 50-mg or 100-mg single test dose, with a determination of the plasma level 24 hours later. Because the 50-mg or 100-mg test dose used in previous studies may cause unmanageable acute side effects in elderly patients, a 25-mg NT te...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Schneider LS,Cooper TB,Staples FR,Sloane RB

    更新日期:1987-10-01 00:00:00

  • Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.

    abstract:BACKGROUND:Combination antipsychotics (CAs) are prescribed in schizophrenia despite limited evidence of efficacy. To explore the effect of switching from CA to monotherapy, we performed an exploratory analysis of the PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared with Injectables: Evaluati...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000766

    authors: Foster A,Buckley P,Lauriello J,Looney S,Schooler N

    更新日期:2017-10-01 00:00:00

  • Desipramine plasma levels and response in elderly melancholic patients.

    abstract::The relationship of response and plasma desipramine concentrations was examined in elderly depressed patients to determine whether they were more sensitive to the antidepressant effects of the drug and whether they would respond at lower plasma concentrations than younger patients. Twenty-five inpatients over the age ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Nelson JC,Jatlow PI,Mazure C

    更新日期:1985-08-01 00:00:00

  • Quetiapine Extended Release Open-Label Treatment Associated Changes in Amygdala Activation and Connectivity in Anxious Depression: An fMRI Study.

    abstract:BACKGROUND:This study investigated extended release quetiapine (quetiapine XR) associated changes in functional MRI (fMRI) measures of task-induced amygdalar activation and resting state connectivity in anxious unipolar major depressive disorder (AMDD). METHODS:Anxious unipolar major depressive disorder patients (n = ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000600

    authors: Altinay M,Karne H,Beall E,Anand A

    更新日期:2016-12-01 00:00:00

  • Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.

    abstract::Apoptosis has been considered to be involved in schizophrenia. Water channels are modulated just before apoptosis. In the aquaporin family, aquaporin 4 (AQP-4) is most highly expressed in the brain and is supposed to play an important role in a neuronal environment. In this clinical study, we investigated the relation...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e31825370f4

    authors: Chung TS,Lung FW

    更新日期:2012-06-01 00:00:00

  • Characterizing anticholinergic abuse in community mental health.

    abstract::To identify factors associated with anticholinergic abuse in patients taking antipsychotics and anticholinergics and to document the extent of extrapyramidal side effects in anticholinergic abusers, 21 anticholinergic abusers were matched with 21 controls without a history of anticholinergic abuse for diagnosis and an...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Wells BG,Marken PA,Rickman LA,Brown CS,Hamann G,Grimmig J

    更新日期:1989-12-01 00:00:00

  • Fluoxetine alters the effects of intravenous cocaine in humans.

    abstract::Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse. Oral capsules were ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Walsh SL,Preston KL,Sullivan JT,Fromme R,Bigelow GE

    更新日期:1994-12-01 00:00:00

  • Treatment-resistant catatonic stupor and combined lithium-neuroleptic therapy: a case report.

    abstract::A case of treatment-resistant catatonic stupor responding to combined lithium-neuroleptic medications is described. As there are no reports in the literature of combined lithium-neuroleptic medications being effective for this potentially life-threatening disorder, the course of recovery is detailed and the risks and ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Climo LH

    更新日期:1985-06-01 00:00:00

  • Platelet monoamine oxidase response to lithium treatment in psychiatric patients.

    abstract::Platelet monoamine oxidase (MAO) activity was studied in bipolar and schizophrenic patients treated with lithium and was found to be increased as a nonspecific drug effect. Greater MAO increase in manic patients was correlated with lesser clinical improvement. There was no correlation of MAO activity with short-term o...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Huang LG,Bowden CL

    更新日期:1984-12-01 00:00:00

  • Antipsychotic Use and the Risk of Initiating Medication for Benign Prostate Hyperplasia in Persons With Alzheimer Disease: A Matched Cohort Study.

    abstract:BACKGROUND:Antipsychotics (APs) are known to exacerbate symptoms of benign prostate hyperplasia (BPH) and may even cause urinary retention. The anticholinergic effects of APs and their dopamine D2- and α-receptor blockade may lead to voiding dysfunction of BPH patients. The objective of our study was to investigate whe...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000928

    authors: Orsel K,Taipale H,Raatikainen S,Lampela P,Tolppanen AM,Koponen M,Tanskanen A,Tiihonen J,Gardarsdottir H,Hartikainen S

    更新日期:2018-10-01 00:00:00

  • Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.

    abstract::This research compared the long-term efficacy and safety of iloperidone with those of haloperidol in individuals with schizophrenia. Data were pooled from 3 prospective multicenter studies, each with 6-week stabilization followed by 46-week double-blind maintenance phases. Patients were randomized to iloperidone 4 to ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/JCP.0b013e318169cca7

    authors: Kane JM,Lauriello J,Laska E,Di Marino M,Wolfgang CD

    更新日期:2008-04-01 00:00:00

  • Effects of age and sex on olanzapine plasma concentrations.

    abstract::Age and sex may influence both efficacy and side effects of second-generation antipsychotics. Women and elderly patients tend to have a higher prevalence for several side effects. Higher plasma levels in these groups of patients may be one reason. We studied the hypothesis that steady-state olanzapine plasma concentra...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000185427.08268.db

    authors: Weiss U,Marksteiner J,Kemmler G,Saria A,Aichhorn W

    更新日期:2005-12-01 00:00:00